Ocular Therapeutix (OCUL) Competitors

Ocular Therapeutix logo
$6.01 -0.20 (-3.22%)
Closing price 04:00 PM Eastern
Extended Trading
$6.06 +0.05 (+0.83%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OCUL vs. BLTE, MANE, DFTX, ARQT, and LQDA

Should you buy Ocular Therapeutix stock or one of its competitors? Ocular Therapeutix's main competitors and comparable companies include Belite Bio (BLTE), Veradermics (MANE), Definium Therapeutics (DFTX), Arcutis Biotherapeutics (ARQT), and Liquidia (LQDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Ocular Therapeutix compare to Belite Bio?

Ocular Therapeutix (NASDAQ:OCUL) and Belite Bio (NASDAQ:BLTE) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability.

Ocular Therapeutix has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Belite Bio has a beta of -1.19, indicating that its stock price is 219% less volatile than the broader market.

Belite Bio has lower revenue, but higher earnings than Ocular Therapeutix. Belite Bio is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$51.95M26.30-$265.94M-$1.46N/A
Belite BioN/AN/A-$77.61M-$2.73N/A

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 13.3% of Belite Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Ocular Therapeutix had 15 more articles in the media than Belite Bio. MarketBeat recorded 35 mentions for Ocular Therapeutix and 20 mentions for Belite Bio. Belite Bio's average media sentiment score of 0.60 beat Ocular Therapeutix's score of -0.06 indicating that Belite Bio is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocular Therapeutix
6 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Belite Bio
2 Very Positive mention(s)
6 Positive mention(s)
9 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Belite Bio has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -648.64%. Belite Bio's return on equity of -9.95% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
Ocular Therapeutix-648.64% -59.95% -46.75%
Belite Bio N/A -9.95%-9.76%

Ocular Therapeutix currently has a consensus target price of $23.83, indicating a potential upside of 283.79%. Belite Bio has a consensus target price of $226.27, indicating a potential upside of 37.68%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, equities analysts clearly believe Ocular Therapeutix is more favorable than Belite Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Belite Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67

Summary

Ocular Therapeutix beats Belite Bio on 9 of the 16 factors compared between the two stocks.

How does Ocular Therapeutix compare to Veradermics?

Ocular Therapeutix (NASDAQ:OCUL) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk.

In the previous week, Ocular Therapeutix had 13 more articles in the media than Veradermics. MarketBeat recorded 35 mentions for Ocular Therapeutix and 22 mentions for Veradermics. Veradermics' average media sentiment score of 0.86 beat Ocular Therapeutix's score of -0.06 indicating that Veradermics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocular Therapeutix
6 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Veradermics
9 Very Positive mention(s)
6 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Veradermics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -648.64%. Veradermics' return on equity of -20.50% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
Ocular Therapeutix-648.64% -59.95% -46.75%
Veradermics N/A -20.50%-17.66%

Veradermics has lower revenue, but higher earnings than Ocular Therapeutix. Veradermics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$51.95M26.30-$265.94M-$1.46N/A
VeradermicsN/AN/A-$70M-$1.90N/A

Ocular Therapeutix currently has a consensus target price of $23.83, suggesting a potential upside of 283.79%. Veradermics has a consensus target price of $174.57, suggesting a potential upside of 35.14%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, research analysts plainly believe Ocular Therapeutix is more favorable than Veradermics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Veradermics
1 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.67

59.2% of Ocular Therapeutix shares are held by institutional investors. 3.1% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Ocular Therapeutix beats Veradermics on 10 of the 15 factors compared between the two stocks.

How does Ocular Therapeutix compare to Definium Therapeutics?

Ocular Therapeutix (NASDAQ:OCUL) and Definium Therapeutics (NASDAQ:DFTX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Definium Therapeutics has a net margin of 0.00% compared to Ocular Therapeutix's net margin of -648.64%. Definium Therapeutics' return on equity of -53.23% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
Ocular Therapeutix-648.64% -59.95% -46.75%
Definium Therapeutics N/A -53.23%-43.90%

59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Definium Therapeutics has lower revenue, but higher earnings than Ocular Therapeutix. Definium Therapeutics is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$51.95M26.30-$265.94M-$1.46N/A
Definium TherapeuticsN/AN/A-$183.79M-$3.11N/A

In the previous week, Ocular Therapeutix had 10 more articles in the media than Definium Therapeutics. MarketBeat recorded 35 mentions for Ocular Therapeutix and 25 mentions for Definium Therapeutics. Definium Therapeutics' average media sentiment score of 0.49 beat Ocular Therapeutix's score of -0.06 indicating that Definium Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocular Therapeutix
6 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Definium Therapeutics
4 Very Positive mention(s)
5 Positive mention(s)
11 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Ocular Therapeutix presently has a consensus target price of $23.83, suggesting a potential upside of 283.79%. Definium Therapeutics has a consensus target price of $66.24, suggesting a potential upside of 106.47%. Given Ocular Therapeutix's higher probable upside, equities analysts plainly believe Ocular Therapeutix is more favorable than Definium Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Definium Therapeutics
1 Sell rating(s)
0 Hold rating(s)
19 Buy rating(s)
1 Strong Buy rating(s)
2.95

Ocular Therapeutix has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market.

Summary

Definium Therapeutics beats Ocular Therapeutix on 8 of the 15 factors compared between the two stocks.

How does Ocular Therapeutix compare to Arcutis Biotherapeutics?

Ocular Therapeutix (NASDAQ:OCUL) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Ocular Therapeutix had 27 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 35 mentions for Ocular Therapeutix and 8 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 0.61 beat Ocular Therapeutix's score of -0.06 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Ocular Therapeutix
6 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral
Arcutis Biotherapeutics
1 Very Positive mention(s)
3 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

59.2% of Ocular Therapeutix shares are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ocular Therapeutix presently has a consensus price target of $23.83, suggesting a potential upside of 283.79%. Arcutis Biotherapeutics has a consensus price target of $39.75, suggesting a potential upside of 40.66%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, equities research analysts clearly believe Ocular Therapeutix is more favorable than Arcutis Biotherapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ocular Therapeutix
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82
Arcutis Biotherapeutics
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80

Arcutis Biotherapeutics has a net margin of 5.88% compared to Ocular Therapeutix's net margin of -648.64%. Arcutis Biotherapeutics' return on equity of 14.18% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
Ocular Therapeutix-648.64% -59.95% -46.75%
Arcutis Biotherapeutics 5.88%14.18%6.28%

Ocular Therapeutix has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the broader market.

Arcutis Biotherapeutics has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ocular Therapeutix$51.95M26.30-$265.94M-$1.46N/A
Arcutis Biotherapeutics$508.68M7.03-$16.14M$0.21134.57

Summary

Arcutis Biotherapeutics beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.

How does Ocular Therapeutix compare to Liquidia?

Liquidia (NASDAQ:LQDA) and Ocular Therapeutix (NASDAQ:OCUL) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Liquidia currently has a consensus price target of $75.23, suggesting a potential upside of 31.04%. Ocular Therapeutix has a consensus price target of $23.83, suggesting a potential upside of 283.79%. Given Ocular Therapeutix's stronger consensus rating and higher probable upside, analysts clearly believe Ocular Therapeutix is more favorable than Liquidia.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Liquidia
1 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.50
Ocular Therapeutix
1 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.82

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 3.1% of Ocular Therapeutix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Liquidia has higher revenue and earnings than Ocular Therapeutix. Liquidia is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Liquidia$158.32M32.68-$68.92M-$1.23N/A
Ocular Therapeutix$51.95M26.30-$265.94M-$1.46N/A

In the previous week, Liquidia had 2 more articles in the media than Ocular Therapeutix. MarketBeat recorded 37 mentions for Liquidia and 35 mentions for Ocular Therapeutix. Liquidia's average media sentiment score of 0.62 beat Ocular Therapeutix's score of -0.06 indicating that Liquidia is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Liquidia
10 Very Positive mention(s)
5 Positive mention(s)
11 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Ocular Therapeutix
6 Very Positive mention(s)
3 Positive mention(s)
12 Neutral mention(s)
1 Negative mention(s)
2 Very Negative mention(s)
Neutral

Liquidia has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 1.22, indicating that its stock price is 22% more volatile than the broader market.

Liquidia has a net margin of -15.15% compared to Ocular Therapeutix's net margin of -648.64%. Liquidia's return on equity of 264.65% beat Ocular Therapeutix's return on equity.

Company Net Margins Return on Equity Return on Assets
Liquidia-15.15% 264.65% 44.19%
Ocular Therapeutix -648.64%-59.95%-46.75%

Summary

Liquidia beats Ocular Therapeutix on 11 of the 16 factors compared between the two stocks.

Get Ocular Therapeutix News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCUL vs. The Competition

MetricOcular TherapeutixPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.38B$13.75B$7.85B$12.17B
Dividend YieldN/A2.58%2.46%4.41%
P/E RatioN/A26.0432.9127.37
Price / Sales25.457.318.595.73
Price / CashN/A15.7421.9322.50
Price / Book3.015.144.403.70
Net Income-$265.94M$2.88B$3.52B$392.17M
7 Day Performance-12.26%-3.87%-5.34%-4.53%
1 Month Performance-12.52%-3.96%-3.61%-5.86%
1 Year Performance-46.81%-7.13%0.01%-7.78%

Ocular Therapeutix Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCUL
Ocular Therapeutix
2.286 of 5 stars
$6.01
-3.2%
$23.83
+296.6%
-45.0%$1.38B$51.95MN/A325
BLTE
Belite Bio
3.2192 of 5 stars
$157.69
+2.3%
$227.40
+44.2%
+40.8%$6.20BN/AN/A41
MANE
Veradermics
3.0378 of 5 stars
$143.44
+3.4%
$172.43
+20.2%
N/A$5.70BN/AN/A21
DFTX
Definium Therapeutics
3.119 of 5 stars
$35.39
+6.4%
$66.00
+86.5%
+182.6%$4.39BN/AN/A40
ARQT
Arcutis Biotherapeutics
4.1781 of 5 stars
$26.20
+2.5%
$39.75
+51.7%
+13.0%$4.28B$376.07M162.14354

Related Companies and Tools


This page (NASDAQ:OCUL) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners